In the Drug Profile by Sebastian Schellong, ‘Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease’, which appeared in the July 2013 issue of Expert Review of Cardiovascular Therapy (11[7], 817–828 [2013]; www.expert-reviews.com/doi/full/10.1586/14779072.2013.811979), it has been brought to our attention that the following inaccuracies had appeared:
The citation of the four individual RECORD studies (references 34–37) to support the ‘RECORD1–4 Pooled’ data in Table 2 is incorrect. The correct reference for the pooled analysis is reference 40 (Turpie AGG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 105[3], 444–453 [2011]).
In addition, on page 821, the following sentence is incorrect:
“If the patient’s assessed risk of bleeding outweighs the risk of recurrent DVT or PE, a reduction of the dose from rivaroxaban 20–15 mg q.d. should be considered.”
This should have appeared as:
“If the patient’s assessed risk of bleeding outweighs the risk of recurrent DVT or PE, a reduction of the dose from rivaroxaban 20 mg q.d. to 15 mg q.d. should be considered.”
On page 821, the following sentence is also incorrect:
“Owing to a decrease in solubility at doses above 15 mg q.d., the doses approved for DVT or PE treatment should be given with food.”
This should have appeared as:
“Owing to a decrease in solubility at doses of 15 mg q.d. or above, the doses approved for DVT or PE treatment should be given with food.”
On page 823, the second listed weight range, “60–90 kg,” was also published incorrectly. The correct weight range is “60–<90 kg” on both line 17 and within the parentheses on line 18 in the right-hand column.
The authors and editors of Expert Review of Cardiovascular Therapy would like to sincerely apologise for any confusion or inconvenience this may have caused.